Anavex Life Sciences Corp (AVXL)
$7.53 -$0.22 (-2.82%) 4:42 PM 05/30/25
NASDAQ | $USD | BiotechnologyStock Data
-
Market Cap
$642.85M -
Day's Range
$7.31 - $7.62 -
Volume
991,661 -
52 Week Low / High
$3.51 - $14.44 -
PE Ratio
- -
PEG Ratio
- -
Dividend Frequency
-
- Capital Growth
- Dividend Return to Date
- Dividend Payout year Est.
- Expenses
- Total Return
- Total Return %
- 2
- Strong Buy
- 1
- Buy
- 0
- Hold
- 0
- Sell
- 0
- Strong Sell
- $34.33
- Target Price
Company News
-
ATTENTION-AD trial data through 192 weeks presented at AD/PDTM 2025 Conference Prespecified delayed-start analysis indicate disease-modifying effect of oral blarcamesine and importance of early and continued long-term treatment of chronic Alzheimer’s disease Blarcamesine exhibited a fa...
-
Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference — Mar 31st, 2025
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopment...
-
Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio — Jan 27th, 2025
NEW YORK, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmenta...
Portfolio
Comprised of 1 portfolios